IQVIA Q3 Revenue Rises 8% to $4.43 Billion; Raises 2026 Guidance

What happened

IQVIA reported third-quarter 2026 revenue of $4.43 billion, up 8.0% from a year earlier. Adjusted diluted EPS was $3.34, up 11.3%, and net income was $350 million. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and adjusted diluted EPS.

Confirmed

Global impact / market context

Higher revenue and profit, plus raised full-year guidance, suggest IQVIA expects demand for its drug-development and commercial services to stay strong. That can support spending on staff and technology, and may lift investor confidence in future earnings.

Analyst inference

Research & Development Solutions grew 8.7% with net new bookings of $3.2 billion, up 15%, which means new signed business. A $32.6 billion backlog, which is contracted future work, gives visibility into future revenue for the company.

Analyst inference

What to watch

1. Free cash flow was $667 million and operating cash flow was $825 million in the quarter, showing cash generated after capital spending, which can fund debt repayment or reinvestment. Confirmed
2. Watch whether IQVIA converts its $32.6 billion contracted backlog into revenue on schedule, since delays in customer trials or cancellations could slow reported growth. Proposed
3. Track whether the raised 2026 revenue guidance of $17.35 billion–$17.50 billion is met, because falling short could weaken investor confidence in management forecasts. Analyst inference

Evidence

• Original source link unavailable